Leqvio is owned by Novartis.
Leqvio contains Inclisiran Sodium.
Leqvio has a total of 20 drug patents out of which 4 drug patents have expired.
Expired drug patents of Leqvio are:
Leqvio was authorised for market use on 22 December, 2021.
Leqvio is available in solution;subcutaneous dosage forms.
Leqvio can be used as as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene.
Drug patent challenges can be filed against Leqvio from 2025-12-22.
The generics of Leqvio are possible to be released after 25 August, 2036.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(1 year, 2 months ago) | |
US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(1 year, 1 month ago) | |
US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(3 months ago) | |
US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(4 months from now) | |
US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(6 months from now) | |
US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(9 months from now) | |
US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(9 months from now) | |
US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(9 months from now) | |
US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(11 months from now) | |
US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(3 years from now) | |
US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(10 months ago) | |
US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(4 months from now) | |
US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(4 years from now) | |
US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 2025-12-22
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION;SUBCUTANEOUS
815
United States
184
European Union
139
Australia
126
Japan
86
Canada
31
Germany
18
Spain
18
Austria
18
China
15
Denmark
13
United Kingdom
13
Mexico
12
Hong Kong
9
Portugal
8
Korea, Republic of
6
Israel
6
Cyprus
5
EA
5
New Zealand
4
South Africa
3
Poland
3
Norway
3
Slovenia
3
Brazil
3
Hungary
2
Russia
2
Lithuania
1
Luxembourg
1
Croatia
1
IB
1
Netherlands
1
Indonesia
1
Chile
1
Singapore
1
Argentina
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic